



(Patient Sticker)



PHYSICIAN ORDER SET :

INFLIXIMAB GI LOAD (SCHEDULE WEEKS 0, 2, 6)

CDH 208-203 – Approved 2/18 - Page 1 of 5

Patient: _____

DOB: _____

Gender: _____

Patient Phone #: _____

Height: _____

Weight: _____

Diagnosis: _____

ICD-10 Code: _____

Treatment Start Date: _____

Provider Facility Name: _____

Provider Facility Address: _____

Ordering Provider: _____

Date: _____

Signature: _____

*Complete, Sign, and fax this document to: **CDH Central Scheduling at 413-582-2183***

****Please include H&P/current medications list/allergies, and ensure that med authorizations have been obtained****



(Patient Sticker)

PHYSICIAN ORDER SET :

INFLIXIMAB GI LOAD (SCHEDULE WEEKS 0, 2, 6)

CDH 208-203 – Approved 2/18 - Page 2 of 5

Payor Requirements	Interval	Defer Until	Duration
<input type="checkbox"/> Provider Communication	Once		Until discont'd

Select Diagnosis/Indication for use of Infliximab, or choose other:

Ulcerative Colitis:

- | | |
|--|---|
| <p>1. Has the patient had inadequate response to or have contraindications to an appropriate trial with two or more of the following agents: corticosteroids, 5-aminosalicylates (i.e. sulfasalazine), 6-mercaptopurine, azathioprine, cyclosporine, methotrexate?
<input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>3. Has patient had appropriate TB screening within 6 months of initiating therapy?
<input type="checkbox"/> Yes <input type="checkbox"/> No</p> | <p>2. Has the patient tried and failed treatment with adalimumab (Humira)?
<input type="checkbox"/> Yes
<input type="checkbox"/> No</p> |
|--|---|

Non-fistulizing Crohn's Disease:

- | | |
|--|---|
| <p>1. Has the patient had inadequate response to or have contraindications to an appropriate trial with two or more of the following agents: corticosteroids, 5-aminosalicylates (i.e. sulfasalazine), 6-mercaptopurine, azathioprine, cyclosporine, methotrexate?
<input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>3. Has patient had appropriate TB screening within 6 months of initiating therapy?
<input type="checkbox"/> Yes <input type="checkbox"/> No</p> | <p>2. Has the patient tried and failed treatment with adalimumab (Humira)?
<input type="checkbox"/> Yes <input type="checkbox"/> No</p> |
|--|---|

Fistulizing Crohn's Disease:

- | | |
|---|--|
| <p>1. Has the patient had inadequate response to or have contraindications to an appropriate trial with two or more of the following agents: corticosteroids, 5-aminosalicylates (i.e. sulfasalazine), 6-mercaptopurine, azathioprine, cyclosporine, methotrexate?
<input type="checkbox"/> Yes <input type="checkbox"/> No</p> | <p>2. Has patient had appropriate TB screening within 6 months of initiating therapy?
<input type="checkbox"/> Yes <input type="checkbox"/> No</p> |
|---|--|

Other:

Please document here the diagnosis/indication for this patient to receive Infliximab therapy, as well as any supporting documentation for its medical necessity:

If **No** to one or more questions above, please add documentation to support medical necessity:



PHYSICIAN ORDER SET :

INFLIXIMAB GI LOAD (SCHEDULE WEEKS 0, 2, 6)

CDH 208-203 – Approved 2/18 - Page 3 of 5

Pre-Medications

	Interval	Defer Until	Duration
<input type="checkbox"/> acetaminophen (TYLENOL) tablet 650 mg 650 mg, Oral, Once, Starting S, For 1 Doses <i>Administer at least 30 mins prior to treatment.</i>	Every 2 weeks		3 treatments
<input type="checkbox"/> diphenhydramine (BENADRYL) tablet 25 mg 25 mg, Oral, Once, Starting at treatment start time, For 1 dose <i>HOLD IF: Given IV. Administer at least 30 mins prior to treatment.</i>	Every 2 weeks		3 treatments
<input type="checkbox"/> diphenhydramine (BENADRYL) injection 25 mg 25 mg, Intravenous, Once as needed, If unable to take PO, when released, For 1 dose <i>HOLD IF: Given PO. Administer at least 30 mins prior to treatment.</i>	Every 2 weeks		3 treatments
<input type="checkbox"/> famotidine (PEPCID) tablet 20 mg 20 mg, Oral, Once, Starting at treatment start time, For 1 dose <i>HOLD IF: Given IV. Administer at least 30 mins prior to treatment.</i>	Every 2 weeks		3 treatments
<input type="checkbox"/> famotidine (PF) (PEPCID) injection 20 mg 20 mg, Intravenous, Once as needed, If unable to take PO, Starting when released, For 1 dose <i>HOLD IF: Given PO. Administer at least 30 mins prior to treatment.</i>	Every 2 weeks		3 treatments
<input type="checkbox"/> loratadine (CLARITIN) tablet 10 mg 10 mg, Oral, Once, Starting S, For 1 Doses <i>Administer at least 30 mins prior to treatment.</i>	Every 2 weeks		3 treatments
<input type="checkbox"/> methylprednisolone sodium succinate (SOLU-Medrol) IV 40 mg 40 mg, Intravenous, Once, Starting S, For 1 Doses <i>Administer at least 30 mins prior to treatment.</i>	Every 2 weeks		3 treatments

Medications

	Interval	Defer Until	Duration
<input type="checkbox"/> inFLIXimab (REMICADE) 5 mg/kg 5 mg/kg, Intravenous, Administer over 2 Hours, Once, Starting 30 minutes after treatment start time, For 1 Dose <i>Follow your institutional guidelines for titration and duration of infusion. Use an in-line, sterile, non-pyrogenic, low protein-binding filter of 1.2 micron or LESS.</i>	Every 2 weeks		3 treatments

Catheter management

	Interval	Defer Until	Duration
<input type="checkbox"/> Line Access Routine, Once, Starting S For 1 Occurrences, As needed. Starting when released. Until Specified. <i>Insert peripheral IV, or access peripheral, or central venous access device, to provide treatment.</i>	PRN		Until discont'd
<input type="checkbox"/> alteplase (CATHFLO) 1 mg/mL injection 2 mg 2 mg, Intracatheter, As needed, line care, For central venous access device requiring clearance. Administer per institutional guidelines. May repeat once per lumen., Starting S	PRN		Until discont'd
<input type="checkbox"/> lidocaine-prilocaine (EMLA) cream Topical, As needed, pre procedure/treatment, Apply prior to the PIV insertion or port access, Starting S	PRN		Until discont'd
<input type="checkbox"/> heparin 100 units/mL flush 5 mL 5 mL, Intravenous, As needed, line care, Line care per institutional guidelines, Starting S	PRN		Until discont'd
<input type="checkbox"/> heparin 10 units/mL flush 3 mL 3 mL, Intravenous, As needed, line care, Line care per institutional guidelines, Starting S	PRN		Until discont'd
<input type="checkbox"/> heparin 10 units/mL flush 5 mL 5 mL, Intravenous, As needed, line care, Line care per institutional guidelines, Starting S	PRN		Until discont'd
<input type="checkbox"/> heparin 1000 units/mL flush 2 mL 2 mL, Intracatheter, As needed, line care, APHERESIS LINE CARE ONLY per institutional policy. HEPARIN MUST BE WITHDRAWN FROM EACH LUMEN PRIOR TO FLUSHING OR INFUSING THROUGH THE APHERESIS CATHETER, Starting S	PRN		Until discont'd



PHYSICIAN ORDER SET :

INFLIXIMAB GI LOAD (SCHEDULE WEEKS 0, 2, 6)

CDH 208-203 – Approved 2/18 - Page 4 of 5

Catheter management (continued)

	Interval	Defer Until	Duration
<input type="checkbox"/> sodium chloride (NS) 0.9 % syringe flush 3 mL 3 mL, Intravenous, As needed, line care, Line care per institutional guidelines, Starting S	PRN		Until discont'd
<input type="checkbox"/> sodium chloride (NS) 0.9 % syringe flush 10 mL 10 mL, Intravenous, As needed, line care, Line care per institutional guidelines, Starting S	PRN		Until discont'd
<input type="checkbox"/> sodium chloride (NS) 0.9 % syringe flush 20 mL 20 mL, Intravenous, As needed, line care, Line care per institutional guidelines, Starting S	PRN		Until discont'd
<input type="checkbox"/> sodium chloride 0.9% infusion 20 mL/hr, Intravenous, Continuous PRN, other (free text field), Keep vein open to provide treatment, Starting S	PRN		Until discont'd
<input type="checkbox"/> D5W infusion 20 mL/hr, Intravenous, Continuous PRN, other (free text field), Keep vein open to provide treatment, Starting S	PRN		Until discont'd

Emergency Medications/Anaphylaxis

	Interval	Defer Until	Duration
<input type="checkbox"/> Provider and Nurse Communication Routine, Until discontinued, Starting S, Treatment of SEVERE reaction (ANAPHYLAXIS): hypotension, throat swelling, wheezing, respiratory distress, or decreased oxygen saturation. Stop the infusion and treat with epinephrine FIRST. Notify provider and emergency personnel, administer oxygen as needed, monitor vital signs and proceed with administering adjunct HYPERSENSITIVITY medications as clinically indicated.	PRN		Until discont'd
<input type="checkbox"/> EPINEPHrine injection 0.3 mg 0.3 mg, Intramuscular, As needed, anaphylaxis, Administer FIRST for anaphylaxis. May repeat times 1 dose, Starting S <i>For 2 doses. Pharmacy's Suggested Dose Instructions; Epinephrine 1:1000 is equivalent to 1 mg/mL</i>	PRN		Until discont'd
<input type="checkbox"/> sodium chloride 0.9% bolus 1,000 mL 1,000 mL, Intravenous, Once as needed, other (free text field), For hypotension, Starting S, For 1 Doses	PRN		Until discont'd
<input type="checkbox"/> Oxygen Therapy - Non-Rebreather Routine <i>Select a Mode of Therapy: Non-Rebreather</i>	PRN		Until discont'd

Hypersensitivity continued on next page



(Patient Sticker)

PHYSICIAN ORDER SET :

INFLIXIMAB GI LOAD (SCHEDULE WEEKS 0, 2, 6)

CDH 208-203 – Approved 2/18 - Page 5 of 5

Hypersensitivity

	Interval	Defer Until	Duration
<input type="checkbox"/> Provider and Nurse Communication Routine, Until discontinued, Starting S For Until specified, Treatment for mild-moderate infusion reaction: Stop the infusion, notify provider and emergency personnel, administer oxygen as needed, monitor vital signs and proceed with administering medications as clinically indicated. If ANAPHYLAXIS reaction, refer to Emergency Medications section.	PRN		Until discont'd
<input type="checkbox"/> albuterol (ACCUNEB) nebulizer solution 2.5 mg 2.5 mg, Nebulization, Once as needed, shortness of breath, wheezing, wheezing, shortness of breath, Starting S, For 1 Doses	PRN		Until discont'd
<input type="checkbox"/> acetaminophen (TYLENOL) tablet 975 mg 975 mg, Oral, Once as needed, fever, Starting S, For 1 Doses	PRN		Until discont'd
<input type="checkbox"/> diphenhydrAMINE (BENADRYL) injection 25 mg 25 mg, Intravenous, As needed, itching, itching, hives. Begin with 25 mg. If patient has continued reaction, administer additional 25 mg, Starting S	PRN		Until discont'd
<input type="checkbox"/> famotidine (PEPCID) injection 20 mg 20 mg, Intravenous, Once as needed, other (free text field), Adjunct treatment for mild-moderate, or SEVERE reaction Hold if: given as premed, Starting S, For 1 Doses	PRN		Until discont'd
<input type="checkbox"/> cetirizine (ZyrTEC) tablet 10 mg 10-20 mg, Oral, Once as needed, allergies, Adjunct treatment for mild-moderate, or SEVERE reaction, Starting S, For 1 Doses <i>HOLD IF giving fexofenadine.</i>	PRN		Until discont'd
<input type="checkbox"/> fexofenadine (ALLEGRA) tablet 180 mg 90-180 mg, Oral, Once as needed, allergies, Adjunct treatment for mild-moderate, or SEVERE reaction, Starting S, For 1 Doses <i>HOLD IF giving cetirizine.</i>	PRN		Until discont'd
<input type="checkbox"/> methylprednisolone sodium succinate (SOLU-Medrol) IV 40 mg 40 mg, Intravenous, Once as needed, other (free text field), Adjunct treatment for mild-moderate, or SEVERE reaction, Starting S, For 1 Doses	PRN		Until discont'd
<input type="checkbox"/> ondansetron (ZOFTRAN) injection 4 mg 4 mg, Intravenous, As needed, nausea, vomiting, may repeat x 1 dose, Starting S, For 2 Doses	PRN		Until discont'd
<input type="checkbox"/> meperidine (DEMEROL) injection 25 mg 25 mg, Intravenous, Once as needed, rigors, Starting when released	PRN		Until discont'd